REZDIFFRAREZDIFFRAREZDIFFRA

This indicator is authorized beneath accelerated acceptance according to enhancement of NASH and fibrosis [see Scientific Scientific studies (14)]. Ongoing acceptance for this indication may be contingent upon verification and description of medical gain in confirmatory trials.Underneath is a listing of medicines which will interact with Rezdiffra.